Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2020-04-30 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find enclosed the press release with the title - 'Morepen Laboratories gets ISO-13485 certification for its medical devices manufacturing facility at Baddi (H.P.)'.
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Morepen Laboratories has received ISO-13485 certification for its medical devices manufacturing facility. It details the certification, its significance, and the company's product lines and manufacturing capabilities. There is no financial data, no regulatory filing references, no voting results, no management changes, no earnings or annual report content. The document is clearly a press release about a certification achievement, not a financial or regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-04-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release from Morepen Laboratories Limited announcing the launch and manufacturing of COVID-19 related products such as Infrared Thermometers, Hand Sanitizers, Face Masks, and Hydroxychloroquine. It includes product descriptions, company background, and contact information. There are no financial statements, regulatory certifications, voting results, or management changes. The document is informational and promotional in nature, typical of a press release. It does not contain quarterly or annual financial data, nor does it announce capital changes or legal proceedings. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as a press release announcement that does not fit other specific categories.
2020-04-20 English
Please find enclosed the press release with the title - 'Morepen Labs fights the Covid battle with its Infrared Thermometers, Hand Sanitizers and Face Masks in Indian market'.
Regulatory Filings Classification · 95% confidence The document is a press release from Morepen Laboratories Limited announcing the company's efforts and product launches related to the COVID-19 pandemic, including infrared thermometers, hand sanitizers, face masks, and licensing for Hydroxychloroquine production. It is addressed to stock exchanges and media, providing information about the company's activities and product availability. There are no financial statements, regulatory certifications, voting results, or management changes discussed. The content is promotional and informational about product launches and company initiatives rather than a financial report or regulatory filing. Therefore, the document fits best into the category of a press release, which is generally classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-04-20 English
Please find attached Compliance Certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ....
Regulatory Filings Classification · 100% confidence The document is a compliance certificate pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the half year ended 31st March 2020. It confirms that share transfer activities are maintained by the company's Registrar and Share Transfer Agent. The document is short (1641 characters) and primarily serves as a certification letter to the stock exchanges. It does not contain financial statements or substantive financial data. Therefore, it is not an interim report or annual report but an officer certification related to regulatory compliance. According to the Certification Rule, such documents are classified as Regulatory Filings (RNS).
2020-04-20 English
With reference to Movement in Price, Morepen Laboratories Ltd has submitted to BSE a copy of Clarification is enclosed.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the BSE Limited regarding clarification on price movement of the company's shares. It references compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure obligations. The letter states that there are no pending price sensitive announcements or events. The document is short (1443 characters) and serves as a regulatory communication clarifying the absence of material events affecting share price. It does not contain financial data, report content, or detailed disclosures typical of financial reports or announcements. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement or compliance document that does not fit other categories.
2020-04-09 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India clarifying that there are no pending price sensitive announcements or events that could explain a recent spurt in the company's share price. It references compliance with SEBI (LODR) Regulations, 2015, and states that the price movement is market driven. The document is short (1309 characters) and serves as a regulatory clarification or announcement rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.